Microbiome and immune features in the mouths of e-cigarette smokers, cigarette smokers, and controls revealed a rise in periodontal disease-related bugs and inflammation in vape users.
In the quarter, the firm entered a partnership with Specific Diagnostics and also submitted an enhanced version of its blood culture ID panel for regulatory clearance.
Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.
The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.
The company is developing an RNA sequencing kit based on a technology that enables barcoding in a test tube format to prepare samples for single-cell profiling.
By sequencing ancient Salmonella enterica isolates, investigators retraced the history of the bug in humans transitioning to pastoral and agricultural lifestyles.
The kits can detect more than 1,000 antimicrobial resistance gene variants, including mobilized colistin resistance (mcr) and extended-spectrum beta lactamases.
Last week, GenomeWeb's readers were most interested in Illumina asking a court for a preliminary injunction to prevent BGI from distributing sequencers in the US.
LabCorp will be the exclusive provider of the test, which uses next-generation sequencing to look for actionable mutations cell-free DNA in NSCLC patients.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.
